[EN] NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION [FR] NOUVELLES TÉTRAHYDROPYRIDOPYRIMIDINES ET TÉTRAHYDROPYRIDOPYRIDINES POUR LE TRAITEMENT ET LA PRÉVENTION D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
The synthesis of N-arylpiperidines functionalized both on the aromatic and piperidine ring was performed using conveniently substituted triarylbismuthine derivatives as arylating agents. This method is, in particular, indicated to arylate the nitrogen atom of a secondary amine with a phenyl ring bearing electron-withdrawing groups in the m-position.
Selective Linear Peptides with Melanocortin-4 Receptor (MC4-R) Agonist Activity
申请人:Chen Li
公开号:US20080177036A1
公开(公告)日:2008-07-24
Peptides of formulae I, II and III that selectively activate melanocortin-4 (MC-4) receptor activity.
化学式为I、II和III的肽,可选择性地激活黑色素细胞激素受体-4(MC-4)的活性。
Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection
申请人:Hoffmann-La Roche Inc.
公开号:US10196391B2
公开(公告)日:2019-02-05
The invention provides novel compounds having the general formula:
wherein R1, R2, R3, Q, U, W, Z, X and Y are as described herein, compositions including the compounds and methods of using the compounds. These compounds are HbsAg inhibitors and are useful as medicaments for the treatment or prophylaxis of HBV infection.
本发明提供了具有通式的新型化合物:
其中 R1、R2、R3、Q、U、W、Z、X 和 Y 如本文所述,提供了包括这些化合物的组合物和使用这些化合物的方法。这些化合物是 HbsAg 抑制剂,可用作治疗或预防 HBV 感染的药物。
SELECTIVE LINEAR PEPTIDES WITH MELANOCORTIN-4 RECEPTOR (MC4-R) AGONIST ACTIVITY
申请人:F. Hoffmann-La Roche AG
公开号:EP1272516B1
公开(公告)日:2008-04-23
CYCLIC PEPTIDES HAVING MELANOCORTIN-4 RECEPTOR AGONIST ACTIVITY